Wedbush Analysts Give Sangamo Therapeutics (NASDAQ:SGMO) a $11.00 Price Target

Wedbush set a $11.00 price target on Sangamo Therapeutics (NASDAQ:SGMO) in a research note issued to investors on Monday, Stock Target Advisor reports. The firm currently has a hold rating on the biopharmaceutical company’s stock.

Separately, ValuEngine downgraded W&T Offshore from a hold rating to a sell rating in a research report on Friday, April 26th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $13.33.

NASDAQ SGMO opened at $11.27 on Monday. The stock has a market capitalization of $1.30 billion, a P/E ratio of -16.10 and a beta of 2.99. The company has a quick ratio of 3.98, a current ratio of 3.98 and a debt-to-equity ratio of 0.04. The firm’s fifty day moving average is $9.98. Sangamo Therapeutics has a fifty-two week low of $6.26 and a fifty-two week high of $19.25.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by ($0.14). The company had revenue of $8.07 million for the quarter, compared to analysts’ expectations of $27.21 million. Sangamo Therapeutics had a negative net margin of 113.03% and a negative return on equity of 24.67%. Sell-side analysts anticipate that Sangamo Therapeutics will post -1.46 earnings per share for the current fiscal year.

In other news, CFO Kathy Yi sold 5,000 shares of the business’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $10.00, for a total value of $50,000.00. Following the transaction, the chief financial officer now directly owns 30,512 shares in the company, valued at $305,120. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.30% of the stock is owned by insiders.

Institutional investors have recently made changes to their positions in the company. Wasatch Advisors Inc. increased its holdings in shares of Sangamo Therapeutics by 26.8% in the first quarter. Wasatch Advisors Inc. now owns 6,437,908 shares of the biopharmaceutical company’s stock worth $61,418,000 after purchasing an additional 1,359,170 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Sangamo Therapeutics by 459.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,239,110 shares of the biopharmaceutical company’s stock worth $14,224,000 after acquiring an additional 1,017,573 shares during the last quarter. Sphera Funds Management LTD. bought a new stake in Sangamo Therapeutics during the fourth quarter worth approximately $3,903,000. Bailard Inc. increased its stake in Sangamo Therapeutics by 373.0% during the first quarter. Bailard Inc. now owns 156,100 shares of the biopharmaceutical company’s stock worth $1,489,000 after acquiring an additional 123,100 shares during the last quarter. Finally, SHANDA ASSET MANAGEMENT HOLDINGS Ltd bought a new stake in Sangamo Therapeutics during the fourth quarter worth approximately $1,313,000. Institutional investors and hedge funds own 57.18% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.

Recommended Story: What is a stock split?

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.